Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type.

about

Immunoparesis defined by heavy+light chain suppression is a novel marker of long-term outcomes in cardiac AL amyloidosis.Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis.Light Chain Amyloidosis.

P2860

Q47679443-1010C8A9-3AE3-4600-8449-13ADF2097715 Q48156924-FEEF451A-4D5F-44E6-BB0E-A9DFD50F5FDC Q52659305-B3DB27D4-81D6-4D8C-B595-FDB746548C5B

P2860

Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type.

Item

http://www.wikidata.org/entity/Q41433373

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Immunoparesis status in immuno ...... and survival by regimen type.

@en

type

Item

label

Immunoparesis status in immuno ...... and survival by regimen type.

@en

prefLabel

Immunoparesis status in immuno ...... and survival by regimen type.

@en

P1476

Immunoparesis status in immuno ...... and survival by regimen type.

@en

P2093

Eli Muchtar

http://www.w3.org/2001/XMLSchema#string

Francis K Buadi

http://www.w3.org/2001/XMLSchema#string

John A Lust

http://www.w3.org/2001/XMLSchema#string

Nelson Leung

http://www.w3.org/2001/XMLSchema#string

Prashant Kapoor

http://www.w3.org/2001/XMLSchema#string

Rajshekhar Chakraborty

http://www.w3.org/2001/XMLSchema#string

Ronald S Go

http://www.w3.org/2001/XMLSchema#string

Shaji K Kumar

http://www.w3.org/2001/XMLSchema#string

Yi Lin

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Outcomes After Autologous Hematopoietic Cell Transplantation for Light Chain Amyloidosis: A Center for International Blood and Marrow Transplant Research Study

Poor tolerance to high doses of thalidomide in patients with primary systemic amyloidosis.

Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial.

Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements.

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.

Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement.

Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.

Immunoparesis in newly diagnosed AL amyloidosis is a marker for response and survival.

Ten-year survival after autologous stem cell transplantation for immunoglobulin light chain amyloidosis.

Effect of p53 haploinsufficiency on melphalan-induced genotoxic effects in mouse bone marrow and peripheral blood.

P304

1102-1109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3324/HAEMATOL.2016.147041

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27479823

http://www.w3.org/2001/XMLSchema#string

P932

5060027

http://www.w3.org/2001/XMLSchema#string

Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type.

about

P2860

P2860

Immunoparesis status in immunoglobulin light chain amyloidosis at diagnosis affects response and survival by regimen type.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932